Drreddys Laboratories | RDY - Cash And Equivalent


Drreddys Laboratories reported INR18.66B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
Aurora Cannabis CAD 56.36M 39.33M Dec/2025
Bayer EUR 6.67B 774M Dec/2025
Canopy Growth CAD 371.32M 73.26M Dec/2025
Cipla INR 7.96B 39.9M Sep/2025
Corcept Therapeutics USD 108.74M 11.76M Mar/2026
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Hikma Pharmaceutical USD 236M 48M Jun/2025
Lonza CHF 719M 188M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Pacira USD 144.31M 14.24M Mar/2026
Phibro Animal Health USD 54.93M 557K Mar/2026
Prestige Brands USD 63.87M 1.5M Mar/2026
Richter Gedeon HUF 135.63B 61.59B Dec/2024
Sun Pharmaceuticals INR 113.32B 33.19B Mar/2025
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025